Iambic Raises $150M in IPO for AI Drug Discovery

TL;DR: Iambic Therapeutics announced on October 14, 2026 that it priced 9,375,000 shares at $16.00, for gross proceeds of $150.0 million before underwriting discounts and expenses. Trading on the Nasdaq Global Select Market was expected to start October 15 under the ticker IAM, with the offering expected to close October 16.

It is a clean example of something you will keep seeing: a private, venture-funded company built around AI reaching public investors before any of its drugs is approved.

What did Iambic actually raise, and at what price?

The company also granted underwriters a 30-day option to buy up to 1,406,250 more shares at the same price, per Iambic's announcement.

MedCity News reports the $16 price was the midpoint of the preliminary range. A midpoint price tells you demand was adequate and the underwriters found a number the market would clear on the day. That is a useful fact. It is not a verdict on value, and it does not tell you the shares are cheap.

Where is the money going?

The largest share goes to one drug. According to Fierce Biotech, which read the company's filing, the itemized spending looks like this.

Use of proceeds	Amount	What it funds
IAM1363	$75 million	HER2 inhibitor, current phase 1 plus phase 2 and phase 3 studies
IAM217	$15 million	Taking a KIF18A inhibitor into the clinic
IAM-C1	$15 million	Phase 1 of a dual CDK2/CDK4 inhibitor

The sources reviewed do not itemize the remainder.

So how much of this is an AI bet? You would mostly be buying a cancer drug developer that happens to use AI to find its candidates.

What does the revenue say?

MedCity News reports Iambic booked $12.7 million in collaboration revenue in the first half of the year, up from $3.9 million in the same period last year.

That is partner money, not drug sales, because Iambic has no approved product. Read it as evidence that outside companies pay for the platform, and nothing more.

Who backed it before the public did?

Iambic was founded in 2019 by CEO Tom Miller and CTO Fred Manby, per MedCity News.

Totals for the private funding are reported differently by different outlets, so this article does not quote one. The prospectus is the place to settle it.

For you as an accredited investor, the point is about price. The people who funded those early rounds took the early risk. A buyer today is paying a price they helped set.

What should an accredited investor check before touching it?

Start with what the company says about itself. The company's own press release points to a concrete proof point: a drug candidate, IAM1363, that advanced to the clinic in approximately two years. That is the company's belief about its own platform, in a document written alongside a share sale.

Speed to the clinic is a real milestone, but whether the drug works is a separate question. Fierce Biotech describes IAM1363 as currently in a phase 1 study, which is an early stage.

Then ask how much the stock leans on one asset. With $75 million of the planned spending pointed at IAM1363, per Fierce Biotech, a trial setback there would hit hard.

Common mistakes

The first mistake is treating "AI-driven" as a risk reducer. A faster discovery process does not change the odds that a drug fails once it meets real patients in a human trial, which is where most of the risk has always lived.

The second is reading a $150 million raise as validation. Underwriters priced it at the midpoint, per MedCity News, which is a market-clearing price and nothing grander.

For the wider picture of how IPOs affect private investors, see the piece on the SEC semi-annual reporting rule and IPO exits. To compare with another recent filing, read the OPay US IPO breakdown. And if someone offers you pre-IPO exposure to a name like this, read the Adit Ventures SPV fraud case study first.

FAQ

How much did Iambic raise in its IPO? Iambic raised $150 million in gross proceeds by selling 9,375,000 shares at $16.00, according to its own press release. That is before underwriting discounts and expenses. Underwriters hold an option for more shares.

What is Iambic's ticker? The stock was expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the symbol IAM, per the company's announcement.

What does Iambic make? It develops cancer drugs found with an AI platform. The lead candidate, IAM1363, is an oral HER2 inhibitor in a phase 1 study, per Fierce Biotech.

Can I invest alongside the early backers? Not through this IPO. Their private rounds, the most recent a $100 million round announced nearly a year ago per MedCity News, are already closed. Angel Investors Network does not sell or allocate securities.

What to do today

Open Iambic's registration statement on the SEC's EDGAR database and read the risk factors section before you read any more commentary, this article included.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.